FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible patients with NDMM

Bookmark and Share
Published: 17 Dec 2019
Views: 286
Prof David Cairns - University of Leeds, Leeds, UK

Prof David Cairns speaks to ecancer at the 2019 ASH meeting in Orlando about the FiTNEss study which aims to compare standard and frailty-adjusted induction therapy delivery with patients with transplant non-eligible newly diagnosed multiple myeloma (NDMM).

He describes the rationale and design of this study, which uses a unique frailty score developed by the International Myeloma Working Group to tailor this therapy for older patients.

Prof Cairns explains that this study will open in January 2020 and hopes that the results from this study will encourage the routine use of this frailty score in the clinic.